PT  - JOURNAL ARTICLE
AU  - WAFA BOULEFTOUR
AU  - BENOITE MERY
AU  - ELISE ROWINSKI
AU  - CHARLENE RIVIER
AU  - ELISABETH DAGUENET
AU  - NICOLAS MAGNE
TI  - Cardio-Oncology Preclinical Models: A Comprehensive Review
AID  - 10.21873/anticanres.15348
DP  - 2021 Nov 01
TA  - Anticancer Research
PG  - 5355--5364
VI  - 41
IP  - 11
4099  - http://ar.iiarjournals.org/content/41/11/5355.short
4100  - http://ar.iiarjournals.org/content/41/11/5355.full
SO  - Anticancer Res2021 Nov 01; 41
AB  - Cardiotoxicity is a common side effect induced by cancer therapies, which increases the risk of long-term morbidity and mortality in cancer survivors. To date, the mechanism leading to this toxicity is still unclear, thus complicating cardiac safety assessment and predictive factor identification. The advances in technology, particularly regarding radiation therapy and constant development of novel antineoplastic agents, require urgent development of efficient preclinical models to detect drug cardiotoxicity. A myriad of empirical preclinical models have been used to investigate cardiotoxicity, though with limited success. Recently, multicellular spheroid models have gained attention by mimicking the in vivo microenvironment. The aim of this review is to focus on the most relevant preclinical models used to assess antineoplastic drug- and radiotherapy-related cardiotoxicities, with an overview on their current use. It also aims to discuss the possible directions of translational research in the cardio-oncology field.